EcoDrugPlus

Beta-1 Adrenergic Receptor-Like

Ensembl ID : ENSLBEG00000004043
Gene Symbol: LOC110002297
3 Cross references
196 Possible Orthologues:

Beta-2 Adrenergic Receptor-Like

Ensembl ID : ENSLBEG00000012986
Gene Symbol: LOC109981088
3 Cross references
195 Possible Orthologues:

Beta-Secretase 1

Ensembl ID : ENSLBEG00000012418
Gene Symbol: BACE1
3 Cross references
218 Possible Orthologues:

Bradykinin Receptor B2

Ensembl ID : ENSLBEG00000021174
Gene Symbol: BDKRB2
3 Cross references
155 Possible Orthologues:

Bradykinin Receptor B2

Ensembl ID : ENSLBEG00000004280
Gene Symbol: BDKRB2
2 Cross references
167 Possible Orthologues:

Bradykinin Receptor B2

Ensembl ID : ENSLBEG00000004250
Gene Symbol: BDKRB2
3 Cross references
249 Possible Orthologues:

Breakpoint Cluster Region Protein-Like

Ensembl ID : ENSLBEG00000000698
Gene Symbol: LOC109985945
3 Cross references
196 Possible Orthologues:

Camp-Specific 3',5'-Cyclic Phosphodiesterase 4b-Like

Ensembl ID : ENSLBEG00000011207
Gene Symbol: LOC109996589
2 Cross references
224 Possible Orthologues:

Camp-Specific 3',5'-Cyclic Phosphodiesterase 4c-Like

Ensembl ID : ENSLBEG00000009634
Gene Symbol: LOC109991651
3 Cross references
193 Possible Orthologues:

Calcium Channel, Voltage-Dependent, L Type, Alpha 1c Subunit

Ensembl ID : ENSLBEG00000016300
Gene Symbol: CACNA1C
1 Cross references
213 Possible Orthologues:

Calcium Channel, Voltage-Dependent, L Type, Alpha 1d Subunit, A

Ensembl ID : ENSLBEG00000001621
Gene Symbol: CACNA1DA
1 Cross references
205 Possible Orthologues:

Calcium Channel, Voltage-Dependent, L Type, Alpha 1s Subunit, B

Ensembl ID : ENSLBEG00000008227
Gene Symbol: CACNA1SB
1 Cross references
75 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).